US20160074328A1 - Drug Particles From Freezing Onto A Surface - Google Patents
Drug Particles From Freezing Onto A Surface Download PDFInfo
- Publication number
- US20160074328A1 US20160074328A1 US14/861,046 US201514861046A US2016074328A1 US 20160074328 A1 US20160074328 A1 US 20160074328A1 US 201514861046 A US201514861046 A US 201514861046A US 2016074328 A1 US2016074328 A1 US 2016074328A1
- Authority
- US
- United States
- Prior art keywords
- solution
- drug
- organic solvent
- butanol
- pluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000002245 particle Substances 0.000 title claims abstract description 47
- 238000007710 freezing Methods 0.000 title claims description 21
- 230000008014 freezing Effects 0.000 title claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003960 organic solvent Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 33
- 229940088679 drug related substance Drugs 0.000 claims abstract description 24
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims description 29
- 238000004090 dissolution Methods 0.000 claims description 23
- 239000003381 stabilizer Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 150000002170 ethers Chemical class 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 150000008282 halocarbons Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000013529 heat transfer fluid Substances 0.000 claims description 3
- 238000000859 sublimation Methods 0.000 claims description 3
- 230000008022 sublimation Effects 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 150000003904 phospholipids Chemical group 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 150000002826 nitrites Chemical class 0.000 claims 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 116
- 239000000243 solution Substances 0.000 description 61
- 229920001992 poloxamer 407 Polymers 0.000 description 47
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 46
- 229960002009 naproxen Drugs 0.000 description 46
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 46
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 24
- 229960000766 danazol Drugs 0.000 description 24
- -1 corticosterioids Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 14
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 13
- 229960000623 carbamazepine Drugs 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 239000012738 dissolution medium Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 229960004125 ketoconazole Drugs 0.000 description 8
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 8
- 229960000991 ketoprofen Drugs 0.000 description 8
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 8
- 229960001597 nifedipine Drugs 0.000 description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 8
- 229960004618 prednisone Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 6
- 229930105110 Cyclosporin A Natural products 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960001265 ciclosporin Drugs 0.000 description 6
- 238000003921 particle size analysis Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- 229940052303 ethers for general anesthesia Drugs 0.000 description 5
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 229920002025 Pluronic® F 88 Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical group CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- OMMLUKLXGSRPHK-UHFFFAOYSA-N tetramethylbutane Chemical compound CC(C)(C)C(C)(C)C OMMLUKLXGSRPHK-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AFVDZBIIBXWASR-WAYWQWQTSA-N (Z)-1,3,5-hexatriene Chemical compound C=C\C=C/C=C AFVDZBIIBXWASR-WAYWQWQTSA-N 0.000 description 1
- KYPOHTVBFVELTG-OWOJBTEDSA-N (e)-but-2-enedinitrile Chemical compound N#C\C=C\C#N KYPOHTVBFVELTG-OWOJBTEDSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- UGCSPKPEHQEOSR-UHFFFAOYSA-N 1,1,2,2-tetrachloro-1,2-difluoroethane Chemical compound FC(Cl)(Cl)C(F)(Cl)Cl UGCSPKPEHQEOSR-UHFFFAOYSA-N 0.000 description 1
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 description 1
- SDXUIOOHCIQXRP-UHFFFAOYSA-N 1,2,4,5-tetrafluorobenzene Chemical compound FC1=CC(F)=C(F)C=C1F SDXUIOOHCIQXRP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- AHFMSNDOYCFEPH-UHFFFAOYSA-N 1,2-difluoroethane Chemical compound FCCF AHFMSNDOYCFEPH-UHFFFAOYSA-N 0.000 description 1
- JXUKFFRPLNTYIV-UHFFFAOYSA-N 1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=CC(F)=C1 JXUKFFRPLNTYIV-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZEOVXNVKXIPWMS-UHFFFAOYSA-N 2,2-dichloropropane Chemical compound CC(C)(Cl)Cl ZEOVXNVKXIPWMS-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- FAWUHEYSSPPNSH-UHFFFAOYSA-N 2,3,4-trimethylpent-1-ene Chemical compound CC(C)C(C)C(C)=C FAWUHEYSSPPNSH-UHFFFAOYSA-N 0.000 description 1
- DZPCYXCBXGQBRN-UHFFFAOYSA-N 2,5-Dimethyl-2,4-hexadiene Chemical compound CC(C)=CC=C(C)C DZPCYXCBXGQBRN-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- WPGHPGAUFIJVJF-UHFFFAOYSA-N 3,5-dichloropyridine Chemical compound ClC1=CN=CC(Cl)=C1 WPGHPGAUFIJVJF-UHFFFAOYSA-N 0.000 description 1
- JQZGUQIEPRIDMR-UHFFFAOYSA-N 3-methylbut-1-yn-1-ol Chemical compound CC(C)C#CO JQZGUQIEPRIDMR-UHFFFAOYSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102100035472 DNA polymerase iota Human genes 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001094672 Homo sapiens DNA polymerase iota Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- DIQMPQMYFZXDAX-UHFFFAOYSA-N Pentyl formate Chemical compound CCCCCOC=O DIQMPQMYFZXDAX-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- KFNNIILCVOLYIR-UHFFFAOYSA-N Propyl formate Chemical compound CCCOC=O KFNNIILCVOLYIR-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229940078512 calcium gluceptate Drugs 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- FHADSMKORVFYOS-UHFFFAOYSA-N cyclooctanol Chemical compound OC1CCCCCCC1 FHADSMKORVFYOS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FXPVUWKFNGVHIZ-UHFFFAOYSA-L disodium;dodecyl sulfate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O FXPVUWKFNGVHIZ-UHFFFAOYSA-L 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 239000011551 heat transfer agent Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- XKYICAQFSCFURC-UHFFFAOYSA-N isoamyl formate Chemical compound CC(C)CCOC=O XKYICAQFSCFURC-UHFFFAOYSA-N 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001521 polyalkylene glycol ether Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- KFUSEUYYWQURPO-OWOJBTEDSA-N trans-1,2-dichloroethene Chemical group Cl\C=C\Cl KFUSEUYYWQURPO-OWOJBTEDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B17/00—Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement
- F26B17/28—Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement with movement performed by rollers or discs with material passing over or between them, e.g. suction drum, sieve, the axis of rotation being in fixed position
- F26B17/284—Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement with movement performed by rollers or discs with material passing over or between them, e.g. suction drum, sieve, the axis of rotation being in fixed position the materials being dried on the non-perforated surface of heated rollers or drums
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
- F26B5/065—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/15—Compositions characterised by their physical properties
- A61K6/17—Particle size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Definitions
- the present invention was developed pursuant to a joint research agreement between the Dow Chemical Company and The University of Texas at Austin, a component of the University of Texas System governed by the Board of Regents of the University of Texas System.
- the present invention relates to particles prepared by freezing onto cold solid surfaces, and in particular to the preparation of particles of poorly water soluble pharmaceutical products prepared by freezing onto cold solid surfaces.
- Bioavailability is a term meaning the degree to which a pharmaceutical product, or drug, becomes available to the target tissue after being administered to the body. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. For example, upon oral administration poorly water soluble drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation.
- exposing a drug substance to excessive mechanical shear or exceedingly high temperatures can cause the drug to change or lose activity due to decomposition of the active compound, or due to recrystallyzation processes, i.e., formation of different crystalline polymorphs or transformation, at least in part, from the crystalline to the amorphous state, as described by Florence et al, Effect of Particle Size Reduction on Digoxin Crystal Properties, Journal of Pharmaceutics and Pharmacology, Vol. 26, No. 6, 479-480 (1974), and R. Suryanarayanan and A. G. Mitchell, Evaluation of Two Concepts of Crystallinity Using Calcium Gluceptate as a Model Compound, International Journal of Pharmaceutics, Vol. 24, 1-17 (1985).
- wet milling techniques always result in the presence of a fraction of larger particles, which affects the time for the particles to completely dissolve.
- the present invention is a method for preparing micron-sized or submicron-sized drug particles comprising contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent.
- the present invention is drug particles produced by a method which comprises: contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent.
- the present invention is an apparatus for preparing drug particles comprising: a cold solid surface having a first side and an opposing second side; application means located proximate to the first side of the cold surface, the application means being adapted to permit a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent to be applied to the first side of the cold surface so as to freeze the solution; cooling means located proximate to the second side of the cold surface, the cooling means adapted to cool the cold surface; removal means proximate to the cold surface for removing the frozen solution from the first side of the cold surface; solvent removal means for removing the organic solvent from the frozen solution; and means for transferring the frozen solution from the cold surface to the solvent removal means.
- the present invention has the advantage of being able to process poorly water soluble drug substances, thereby improving the dissolution rates and bioavailability of those drug substances. Moreover, the present invention permits enhanced loading of the drug in the final drug formulation, as compared with those processes described in the above prior art. Moreover, certain aspects of the present invention permit easier processing of the resulting drug particles by avoiding solid-liquid separation steps and/or liquid-liquid separation steps or steps associated with handling cryogenic liquids.
- FIG. 1 is a plan view of one embodiment of an apparatus useful for the present invention.
- FIG. 2 is a plan view of an alternative embodiment of an apparatus useful for the present invention.
- FIG. 3 is a side view of an alternative embodiment of an apparatus useful for the present invention.
- FIG. 1 illustrates a first embodiment 10 of an apparatus that can be used to perform the present invention.
- a solution is first applied to a cold surface.
- the solution comprises a poorly water soluble drug substance and at least one freezable organic solvent.
- poorly water soluble means those drug substances having a solubility in water of less than about 10 mg/ml.
- the present invention has particular applicability to those drug substances having a solubility in water of less than about 1 mg/ml and even as low as 500 ng/ml.
- the drug substance is in essentially pure form and is dispersible in at least one liquid medium.
- Preferred drug substances include those intended for oral administration including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiacinotropic agents, contrast media, corticosterioids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating
- the solution further comprises at least one freezable organic solvent.
- the organic solvent is required to solubilize the poorly water soluble drug.
- the drug substance has a solubility range in the organic solvent of from about 0.1 to about 90 percent by weight.
- Particularly suitable organic solvents are selected from those that freeze at a relatively high temperature and have a boiling point that is relatively close to the freezing point.
- the organic solvent has a freezing point of less than about 100° C. and more preferably less than about 75° C.
- the organic solvent is selected from the group consisting of alcohols, ethers, halocarbons, hydrocarbons, halogenated hydrocarbons, aromatic hydrocarbons, esters, acetates, organic acids, amines, ketones, sulfones, nitriles, carbonates, aldehydes, and combinations thereof.
- Examples of specific suitable organic solvents include ethanol, isobutyl alcohol, methanol, n-butyl alcohol, isopropanol, n-amyl alcohol, n-heptyl alcohol, sec-octyl alcohol, cyclopentanol, n-octyl alcohol, benzyl alcohol, ethylene glycol, cycloheptanol, n-decyl alcohol, cyclooctanol, cyclohexanol, t-butanol, t-amyl alcohol, pentafluorophenol, methyl butynol, hexafluoroisopropanol, 2,2,2-trifluoroethanol, n-hexyl alcohol, 1,3,4-nitrocresol, methyl acetate, isobutyl acetate, n-propyl acetate, ethyl acetate, isoamyl acetate, n-butyl acetate, is
- the freezable organic solvent is selected from methylene chloride, cyclopentanol, t-amyl alcohol, p-xylene, t-butanol, acetonitrile, tetrahydrofuran, cyclohexane, trifluoroethanol, glycolic acid, acetic acid, cyclohexanone, methyl t-butyl ketone, diethyl ketone, and combinations thereof.
- the freezable organic solvent is selected from those generally regarded as being pharmaceutically acceptable.
- the solution further comprises at least one stabilizer.
- the optional stablizer(s) are added after the solution is frozen.
- the stabilizer inhibits crystal growth, aggregation and agglomeration of the drug particles.
- the choice of stabilizer or stabilizers will depend upon the drug molecule. Generally, polymeric stabilizers are preferred. Examples of particle stabilizers include phospholipids, surfactants, polymeric surfactants, vesicles, polymers, including copolymers and homopolymers and biopolymers, and/or dispersion aids.
- Suitable surfactants include gelatin, casein, lecithin, phosphatides, gum acacia, cholesterol, tragacanth, fatty acids and fatty acid salts, benzalkonium chloride, glycerol mono and di fatty acid esters and ethers, cetostearyl alcohol, cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens, polyethylene glycols, poly(ethylene oxide/propylene oxide) copolymers, e.g., the commercially available Poloxomers or Pluronics, polyoxyethylene fatty acid ethers, e.g., the commercially available Brijs, polyoxyethylene fatty acid esters, sorbitan fatty acid esters, e.g., the commercially available Spans, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium,
- the amount of stabilizer added to the solution will depend upon the dosage form of the drug and the type of drug.
- the stabilizer is added to the solution in a concentration of less than 90%, more preferably less than 70% and even more preferably less than 50%.
- water can optionally added to the solution in order to assist in solubilizing the stabilizer, even though water would not be useful to solubilize the poorly water soluble drug.
- the stabilizer is characterized as a surfactant.
- surfactants that can be advantageously employed herein can be readily determined by those skilled in the art and include various nonionic, anionic, cationic, and amphoteric surfactants, or a blend of those surfactants.
- Preferred surfactants are those which significantly reduce the tendency for the oil droplets of the discontinuous phase to agglomerate.
- nonionic surfactants include the polyalkylene glycol ethers and condensation products of aliphatic alcohols, aliphatic amines, or fatty acids with ethylene oxide or propylene oxide; polyvinyl alcohols of different molecular weights and degree of hydrolyzation; polyvinyl pyrrolidones; and the surfactants of the Brij, Tween, and Span series.
- Anionic surfactants include salts of alkyl aryl sulphonic acids, sulphated polyglycol ethers, and ethers of sulphosuccinic acid.
- Cationic surfactants include quaternary ammonium compounds and fatty amines.
- the cold solid surface comprises a first side and an opposing second side.
- the solution is applied to the cold solid surface by way of application means located proximate to the first side of the cold solid surface.
- sprayer 11 is the means for applying the solution to the cold surface.
- Sprayer 11 can be a standard, commercially available sprayer or can be a specially-designed sprayer. Any means for applying the solution to the cold surface can be used, such as means utilizing gravity, utilizing a difference in pressure, utilizing an electric charge and/or utilizing a temperature differential.
- a dropper 21 such as that shown in FIG. 2 may be used to apply the solution to the cold surface in dropwise fashion, or a roller, a brush or other capillary action applicator may be used.
- vacuum may be used to pull the solution onto the cold surface.
- Other types of application means known to those skilled in the art may be used as well.
- the cold solid surface comprises a cylinder 12 that is capable of being maintained at low temperatures and can be rotated.
- any solid surface may be used, and it is not necessary that the surface be curved or that it move.
- a flat solid surface may also be used, or a curved surface that does not rotate may be used as well, so long as the surface is in a sold state and can be maintained at very low temperatures so as to substantially freeze the solution upon contact.
- Examples of solid surfaces include but are not limited to a rotating drum, a belt, a tray and the like.
- the rate at which the solution is applied to the cold surface should be sufficient such that the solution is substantially frozen soon after contact with the cold surface.
- the solution is substantially frozen in less than one minute upon contact with the cold surface. More preferably, the solution is applied to the cold surface such that the solution substantially freezes in less than one second upon contact with the cold surface.
- the solution should be applied to the surface such that the thickness of the resulting film layer of solution formed on the cold surface is sufficient to freeze within seconds upon contact.
- the rate of application results in a film thickness of less than 5 millimeters, more preferably, less than about 1 mm, even more preferably less than about 0.2 mm, and yet even more preferably less than about 0.05 mm. If the film of solution is not substantially frozen within seconds of contact with the cold surface, the solution is being applied too quickly.
- the material of construction for the cold surface can be any material that is capable of being cooled to the desired temperature.
- the material of construction is one that enables good heat transfer.
- particularly suitable materials of construction for the cold surface include metals, metal alloys, glass, and ceramics.
- the temperature at which the solution is held prior to being applied to the cold surface is not critical.
- the present invention includes cooling means located proximate to the second side of the cold solid surface, the cooling means adapted to cool the surface.
- the cooled solid surface can be cooled using any suitable means, including those utilizing a cryogenic solid, a cryogenic gas, a cryogenic liquid, or a heat transfer fluid capable of reaching cryogenic temperatures.
- a cryogenic solid is defined as a material that sublimes below the freezing point of water, such as, for example, carbon dioxide.
- a cryogenic gas means a material that is a gas below the freezing point of water, such as, for example, nitrogen.
- a cryogenic liquid is a material that is liquid below the freezing point of water, such as, for example, liquid nitrogen. In the embodiments shown in FIGS.
- a hole 13 in cylinder 12 permits insertion of dry ice into the inside of cylinder 12 so as to cool the surface of cylinder 12 .
- a cryogenic heat transfer agent 33 such as nitrogen or liquid carbon dioxide may be placed in contact with the cold surface, either directly or indirectly, so as to cool the surface.
- Other means for cooling the surface known to those skilled in the art may be used as well.
- the temperature at which the cold surface should be cooled to will depend upon the organic solvent or solvents used in the solution.
- the cold solid surface should be cooled to a temperature that is below the freezing point of the freezable organic solvent prior to contacting the solution with the cold solid surface so as to ensure that the solution substantially freezes upon contact with the solid surface.
- the difference between the freezing point of the freezable organic solvent and the temperature of the cold surface will impact the rate of freezing of the solution.
- frozen solution is defined to mean poorly water soluble drug particles and, optionally, one or more excipients, suspended in a frozen organic solvent matrix. Such frozen solution is formed once the solution is substantially frozen within seconds after contact with the cold surface.
- the cold surface is cooled to a temperature of at least 5° C. below the freezing point of the organic solvent, more preferably at least 30° C. below the freezing point of the organic solvent, even more preferably at least 50° C. below the freezing point of the organic solvent, and most preferably at least 75° C. below the freezing point of the organic solvent.
- the cold surface is maintained at a low temperature for entire period of time during which the process of the present invention is being carried out.
- the present invention also includes means for removing the frozen solution from the cold surface.
- means for transferring the frozen solution includes a knife blade assembly 14 which flakes the frozen solution off of the cold surface and then allows the frozen solution to be gravity fed to a collecting surface or directly to further processing. Vibration, pressure, a brush or a blower or other methods utilizing a pressure differential are other appropriate means for removing the frozen solution from the cold surface. Alternatively, a non-stick coating on the cold surface would permit automatic removal of the frozen solution.
- FIGS. 1 and 2 also show a product tray 16 used as a collecting surface for the frozen solution once removed from the cylinder 12 , and a secondary tray 17 as optional means for cooling product tray 16 . By cooling the product tray, the solution is kept frozen until ready for further processing.
- Means for transferring the frozen solution to subsequent processing step might be necessary for the present invention as well.
- the frozen solution is gravity fed to the subsequent processing steps.
- a conveyor could be used to transfer the frozen solution.
- Solvent removal means are used to remove the organic solvent from the frozen solution, thereby generating the resulting drug particles.
- Suitable solvent removal means include sublimation and evaporation.
- sublimation techniques include but are not limited to lyophilization and atmospheric freeze drying, as known by those skilled in the art of solvent removal.
- evaporation techniques include but are not limited to distillation techniques and spray drying techniques, as known by those skilled in the art of solvent removal.
- the frozen solution is desirably first dispersed in a liquid that is miscible with the organic solvent but that does not solubilize the drug substance, such as, for example, water.
- the mean volume average particle size of the resulting drug particles after the particles are dispersed in water is from 0.05 microns to 150 microns, as measured using light scattering techniques. More preferably, the mean volume average particle size is 50 microns or less, even more preferably 25 microns or less, yet even more preferably 5 microns or less, and most preferably 1 micron or less.
- the resulting drug particles have a high surface area relative to particles that are not processed using the present invention.
- a high surface area can contribute to a relatively fast dissolution time.
- the particles prepared according to the present invention have a surface area at least 2 m2/g, more preferably at least 5 m2/g, and even more preferably at least 10 m2/g, as measured using BET techniques known to those skilled in the art.
- the drug particles may be combined with any pharmaceutically-acceptable carrier in order to form a pharmaceutical formulation capable of, preferably, oral administration.
- the compositions of the inventions may also include optional excipients such as standard fillers, binders, or disintegrants readily known by those skilled in the art.
- the resulting drug particles exhibit enhanced in vitro dissolution rates as compared to the drug before being processed using the present invention.
- the drug particles processed using the present invention exhibit an in vitro dissolution rate of at least 1.5 times better than that of the unprocessed drug, more preferably at least 5 times better than that of the unprocessed drug, and even more preferably at least 10 times better than that of the unprocessed drug, as measured using standard in vitro dissolution methods known to those skilled in the art. For example, within 2 minutes, if the unprocessed drug is 20% dissolved, then particles processed using the present invention would be at least 30% dissolved.
- the resulting drug particles are substantially crystalline in nature, despite the fact that the present invention involves rapid freezing.
- Cyclosporin A is a drug substance that was purchased from POLI Industria Chimica S.P.A.
- Danazol is a drug substance that was purchased from Spectrum Chemical Co., & Diosynth Co.
- Ketoconazole, ketoprofen, naproxen, nifedipine, prednisone, triamcinalone acetonide, carbamazepine, and hydrocortisone acetate are drug substances that were purchased from the Spectrum Chemical Co.
- Pluronic F-127 is a stabilizer that was purchased from the Sigma Chemical Co.
- Pluronic F-108, Pluronic F-88 are stabilizers that were purchased from the BASF Co.
- Pluronic F-68 polyvinylpyrrolidone (PVP, 10K, 29K, 55K), SPAN 40, SPAN 60, and polyethylene glycol (PEG, 10K), are stabilizers that were purchased from the Aldrich Chemical Co.
- p-Xylene, t-amyl alcohol, 1,3,5-trioxane, sec-butyl acetate and cyclopentanol are solvents that were purchased from the Aldrich Chemical Co.
- t-Butanol, acetonitrile, acetone, tetrahydrofuran and ethyl acetate are solvents that were purchased from Fisher Scientific Co.
- Dissolution obtained using the following method is also referred to herein as “in vitro dissolution”.
- the dissolution media used varied with the drug substance, and is specified below.
- the dissolution media was heated to 37° C. and degassed.
- Dissolution was performed utilizing three vessels per experiment. 11 to 12 mg of drug particles prepared according to the present invention was added to each vessel for dissolution analysis.
- Dissolution samples were filtered automatically into test tubes containing 0.1 mL of acetonitrile, mixed with a vortex mixer, filtered and analyzed by HPLC. Samples were taken at 2, 5, 10, 15, 20, 30, 60, and 120 minutes. At the 60 min. point the agitation speed was increased to 200 rpm to ensures complete dissolution by 120 minutes. The 120 min.
- Dissolution times were measured for the bulk drug substance as received as well as the drug particles prepared according to the present invention for each of Examples 1-60.
- Dissolution Media for the various drug substances used in Examples 1-60 were as follows:
- the dissolution media was deionized water containing 5.0 wt. % sodium chloride.
- the dissolution media was deionized water containing 0.75 wt. % SLS, and 1.21 wt. % Tris(hydroxymethyl)aminomethane, and was adjusted to pH 9.
- the dissolution media was deionized water containing 0.1 wt. % SLS.
- the dissolution media was deionized water containing 0.5 wt. % SLS.
- the dissolution media was deionized water containing 0.3 wt. % SLS and 3.0 wt. % sodium chloride.
- the dissolution media was deionized water containing 10.0 wt. % sodium chloride.
- the dissolution media was deionized water containing 0.3 wt. % sodium sodium dodecylsulfate (SDS).
- Crystallinity was determined by X-ray diffraction methods using a Bruker D-8 automated diffractometer.
- Atmospheric Freeze Drying (ATMFD).
- ATMFD was one method of solvent removal used in the following examples. Heat transfer fluid was circulated through the circulating jacket of the heat exchanger, that was used to cool the drying gas then to the jacket of the ATMFD unit. Chilled nitrogen gas is flowed through the bottom of the ATMFD unit to sublime the solvent(s) away from the drug (s) and fluidizing the solids. The ATMFD unit and the nitrogen gas temperature are slowly warmed to ambient temperature. After the ATMFD portion of the process was complete the solid was collected from either the cyclone or the ATMFD Unit.
- Freeze drying was an alternative solvent removal method used in some of the following examples.
- the frozen solution that was prepared was transferred to ajar cooled with dry ice.
- the processed solid in the chilled container was placed on a Virtis freeze dryer and dried for app. 12-24 hr at approximately 100 mtorr vacuum.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 10/639,361, filed Aug. 12, 2003, which claims priority to U.S. Provisional Application Ser. No. 60/440,535, filed Jan. 15, 2003, the entire contents of each of which are incorporated herein by reference.
- The present invention was developed pursuant to a joint research agreement between the Dow Chemical Company and The University of Texas at Austin, a component of the University of Texas System governed by the Board of Regents of the University of Texas System.
- The present invention relates to particles prepared by freezing onto cold solid surfaces, and in particular to the preparation of particles of poorly water soluble pharmaceutical products prepared by freezing onto cold solid surfaces.
- High bioavailability and short dissolution times are desirable attributes of a pharmaceutical end product. Bioavailability is a term meaning the degree to which a pharmaceutical product, or drug, becomes available to the target tissue after being administered to the body. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. For example, upon oral administration poorly water soluble drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation.
- It is known that the rate of dissolution of a particulate drug can increase with increasing surface area, i.e., decreasing particle size. Consequently, efforts have been made to control the size and size range of drug particles in pharmaceutical compositions. For example, wet milling techniques have been used, as described in U.S. Pat. No. 5,145,684. However, such wet milling techniques exhibit problems associated with contamination from the grinding media. Moreover, exposing a drug substance to excessive mechanical shear or exceedingly high temperatures can cause the drug to change or lose activity due to decomposition of the active compound, or due to recrystallyzation processes, i.e., formation of different crystalline polymorphs or transformation, at least in part, from the crystalline to the amorphous state, as described by Florence et al, Effect of Particle Size Reduction on Digoxin Crystal Properties, Journal of Pharmaceutics and Pharmacology, Vol. 26, No. 6, 479-480 (1974), and R. Suryanarayanan and A. G. Mitchell, Evaluation of Two Concepts of Crystallinity Using Calcium Gluceptate as a Model Compound, International Journal of Pharmaceutics, Vol. 24, 1-17 (1985). In addition, wet milling techniques always result in the presence of a fraction of larger particles, which affects the time for the particles to completely dissolve.
- Other efforts to reduce particle sizes include those such as described in U.S. Pat. Nos. 3,309,777 and 5,780,295. The '777 and '295 patents describes processes which include aerosolizing a biological suspension and impinging the aerosol particles onto a cold collecting surface, thereby encompassing each of the particles in a layer of pure water ice. The frozen aersol particles are then removed from the cold surface and dried. The '777 and '295 patents teach the use of primarily water in the biological suspensions, which is not feasible when using poorly water soluble drug substances. Neither the '777 patent nor the '295 patent addresses the problems encountered when working with poorly water soluble drug substances.
- Yet further efforts aimed at modifying particle structures are described in U.S. Pat. No. 3,932,943 and in WO 02/060411, which describe freezing materials by spraying those materials into a cryogenic liquid. However, the technologies described in these references have problems associated with recovering the particles from the cryogenic liquid, handling of the cryogenic liquid, and environmental issues.
- U.S. Pat. Nos. 3,313,032 and 5,727,333 describe processes for drying materials from solution. However, neither of these patents address the need for improving the bioavailability and dissolution rates of poorly water soluble drug substances.
- It would be an advantage to provide stable poorly water soluble pharmaceutical compositions in the micron or submicron particle size range which have improved bioavailability but do not have the problems associated with the above identified prior art.
- In a first aspect, the present invention is a method for preparing micron-sized or submicron-sized drug particles comprising contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent.
- In a second aspect, the present invention is drug particles produced by a method which comprises: contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent.
- In a third aspect, the present invention is an apparatus for preparing drug particles comprising: a cold solid surface having a first side and an opposing second side; application means located proximate to the first side of the cold surface, the application means being adapted to permit a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent to be applied to the first side of the cold surface so as to freeze the solution; cooling means located proximate to the second side of the cold surface, the cooling means adapted to cool the cold surface; removal means proximate to the cold surface for removing the frozen solution from the first side of the cold surface; solvent removal means for removing the organic solvent from the frozen solution; and means for transferring the frozen solution from the cold surface to the solvent removal means.
- The present invention has the advantage of being able to process poorly water soluble drug substances, thereby improving the dissolution rates and bioavailability of those drug substances. Moreover, the present invention permits enhanced loading of the drug in the final drug formulation, as compared with those processes described in the above prior art. Moreover, certain aspects of the present invention permit easier processing of the resulting drug particles by avoiding solid-liquid separation steps and/or liquid-liquid separation steps or steps associated with handling cryogenic liquids.
-
FIG. 1 is a plan view of one embodiment of an apparatus useful for the present invention. -
FIG. 2 is a plan view of an alternative embodiment of an apparatus useful for the present invention. -
FIG. 3 is a side view of an alternative embodiment of an apparatus useful for the present invention. -
FIG. 1 illustrates a first embodiment 10 of an apparatus that can be used to perform the present invention. A solution is first applied to a cold surface. The solution comprises a poorly water soluble drug substance and at least one freezable organic solvent. As used herein the term “poorly water soluble” means those drug substances having a solubility in water of less than about 10 mg/ml. The present invention has particular applicability to those drug substances having a solubility in water of less than about 1 mg/ml and even as low as 500 ng/ml. - Preferably, the drug substance is in essentially pure form and is dispersible in at least one liquid medium. Preferred drug substances include those intended for oral administration including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiacinotropic agents, contrast media, corticosterioids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasidilators and xanthines. A description of these classes of drugs and a listing of species within each class can be found in Martindale, The Extra Pharmacopoeia, Twenty-ninth Edition, The Pharmaceutical Press, London, 1989, the disclosure of which is hereby incorporate by reference.
- The solution further comprises at least one freezable organic solvent. The organic solvent is required to solubilize the poorly water soluble drug. Preferably, the drug substance has a solubility range in the organic solvent of from about 0.1 to about 90 percent by weight. Particularly suitable organic solvents are selected from those that freeze at a relatively high temperature and have a boiling point that is relatively close to the freezing point. Preferably, the organic solvent has a freezing point of less than about 100° C. and more preferably less than about 75° C. Preferably, the organic solvent is selected from the group consisting of alcohols, ethers, halocarbons, hydrocarbons, halogenated hydrocarbons, aromatic hydrocarbons, esters, acetates, organic acids, amines, ketones, sulfones, nitriles, carbonates, aldehydes, and combinations thereof. Examples of specific suitable organic solvents include ethanol, isobutyl alcohol, methanol, n-butyl alcohol, isopropanol, n-amyl alcohol, n-heptyl alcohol, sec-octyl alcohol, cyclopentanol, n-octyl alcohol, benzyl alcohol, ethylene glycol, cycloheptanol, n-decyl alcohol, cyclooctanol, cyclohexanol, t-butanol, t-amyl alcohol, pentafluorophenol, methyl butynol, hexafluoroisopropanol, 2,2,2-trifluoroethanol, n-hexyl alcohol, 1,3,4-nitrocresol, methyl acetate, isobutyl acetate, n-propyl acetate, ethyl acetate, isoamyl acetate, n-butyl acetate, isopropyl acetate, n-amyl acetate, n-octyl acetate, sec-butyl acetate, toluene, ethylbenzene, m-xylene, o-xylene, p-xylene, mixed xylenes, benzene, cyclohexane, cycoheptane, 1,2,4,5-tetramethylbenzene, cyclopropane, gloxal, paraldhyde, trimethylacetaldehyde, dimethylformamide, beta-picoline, pyridine, morpholine, piperzine, 3,5-dichloropyridine, pyrazine, ethylenediamine, oxazole, diethylamine, triethylamine, methyl amine, dimethyl carbonate, di-t-butyl dicarbonate, methyl formate, isobutyl formate, isoamyl formate, n-propyl formate, ethyl formate, n-amyl formate, and dimethyl oxalate, diethylether, methyl-t-butyl ether, diisopropyl ether, 1,4-dioxane, tetrahydrofuran, 1,3,5-trioxane, p-dioxane, dimethyl ether, P-dichlorobenzene, pentafluorotoluene, hexafluorobenzene, 1,2,4,5-tetrafluorobenzene, 1,3,5-trifluorobenzene, chloroform, methylene chloride, carbon tetrachloride, 1,2-difluoro-1,1,2,2-tetrachloroethane, 1,1,1-trichloro-2,2,2-trifluoroethane, ethylene difluoride, 1,1,1-trichloroethane, 2,2-dichloropropane, 1,1,2-trichloro-1,2,2-trifluoroethane, ethylene dichloride, perfluorocyclobutane, trans-dichloroethylene, 1-bromo-1-chloro-2,2,2-trifluoroethane, and pefluorodecane, trans-1,2-12,-dichlorethene, n-hexane, n-heptane, n-octane, n-decane, 2,2,3,3-tetramethylbutane, bicyclo(2.2.1)hept-2-ene, 2,3,4-trimethyl-1-pentene, 2,5-dimethyl-2,4-hexadiene, tetranitromethane, cis-1,3,5-hexatriene, neopentane, 2,2,3-trimethylbutane, dimethylacetylene, diacetylene, acetone, methyl ethyl ketone, methyl iso-butyl ketone, methyl butyl ketone, cylclopentanone, methyl-t-butyl ketone, diisobutyl ketone, diethyl ketone, dipropyl ketone, cyclohexanone, methyl heptyl ketone, acetonitrile, fumaronitrile, formic acid, glacial acetic acid, glycolic acid, propionic acid, trifluoroacetic acid, dimethyl sulfoxide and combinations thereof. When combinations of solvents are used, the ratios of the solvents used is not critical and will depend upon the desired freezing point of the solution as well as the desired level of dissolution of the particular drug that will be dissolved in the combination of solvents.
- Even more preferably, the freezable organic solvent is selected from methylene chloride, cyclopentanol, t-amyl alcohol, p-xylene, t-butanol, acetonitrile, tetrahydrofuran, cyclohexane, trifluoroethanol, glycolic acid, acetic acid, cyclohexanone, methyl t-butyl ketone, diethyl ketone, and combinations thereof. Most preferably, the freezable organic solvent is selected from those generally regarded as being pharmaceutically acceptable.
- Optionally, the solution further comprises at least one stabilizer. Alternatively, the optional stablizer(s) are added after the solution is frozen. The stabilizer inhibits crystal growth, aggregation and agglomeration of the drug particles. The choice of stabilizer or stabilizers will depend upon the drug molecule. Generally, polymeric stabilizers are preferred. Examples of particle stabilizers include phospholipids, surfactants, polymeric surfactants, vesicles, polymers, including copolymers and homopolymers and biopolymers, and/or dispersion aids. Suitable surfactants include gelatin, casein, lecithin, phosphatides, gum acacia, cholesterol, tragacanth, fatty acids and fatty acid salts, benzalkonium chloride, glycerol mono and di fatty acid esters and ethers, cetostearyl alcohol, cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens, polyethylene glycols, poly(ethylene oxide/propylene oxide) copolymers, e.g., the commercially available Poloxomers or Pluronics, polyoxyethylene fatty acid ethers, e.g., the commercially available Brijs, polyoxyethylene fatty acid esters, sorbitan fatty acid esters, e.g., the commercially available Spans, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), sodium lauryl sulfate, polyvinylpyrrolidone (PVP), poly(acrylic acid), and other anionic, cationic, zwitterionc and nonionic surfactants. Other suitable stabilizers are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986, which is incorporated by reference herein. Such stabilizers are commercially available and/or can be prepared by techniques known in the art.
- Generally, the amount of stabilizer added to the solution will depend upon the dosage form of the drug and the type of drug. Preferably, the stabilizer is added to the solution in a concentration of less than 90%, more preferably less than 70% and even more preferably less than 50%.
- If a stabilizer is used, water can optionally added to the solution in order to assist in solubilizing the stabilizer, even though water would not be useful to solubilize the poorly water soluble drug.
- In one embodiment, the stabilizer is characterized as a surfactant. Surfactants that can be advantageously employed herein can be readily determined by those skilled in the art and include various nonionic, anionic, cationic, and amphoteric surfactants, or a blend of those surfactants. Preferred surfactants are those which significantly reduce the tendency for the oil droplets of the discontinuous phase to agglomerate. Examples of nonionic surfactants include the polyalkylene glycol ethers and condensation products of aliphatic alcohols, aliphatic amines, or fatty acids with ethylene oxide or propylene oxide; polyvinyl alcohols of different molecular weights and degree of hydrolyzation; polyvinyl pyrrolidones; and the surfactants of the Brij, Tween, and Span series. Anionic surfactants include salts of alkyl aryl sulphonic acids, sulphated polyglycol ethers, and ethers of sulphosuccinic acid. Cationic surfactants include quaternary ammonium compounds and fatty amines.
- The cold solid surface comprises a first side and an opposing second side. The solution is applied to the cold solid surface by way of application means located proximate to the first side of the cold solid surface. In the embodiment shown in
FIG. 1 ,sprayer 11 is the means for applying the solution to the cold surface.Sprayer 11 can be a standard, commercially available sprayer or can be a specially-designed sprayer. Any means for applying the solution to the cold surface can be used, such as means utilizing gravity, utilizing a difference in pressure, utilizing an electric charge and/or utilizing a temperature differential. Alternatively, adropper 21 such as that shown inFIG. 2 may be used to apply the solution to the cold surface in dropwise fashion, or a roller, a brush or other capillary action applicator may be used. Alternatively, vacuum may be used to pull the solution onto the cold surface. Other types of application means known to those skilled in the art may be used as well. - In the embodiment shown in
FIGS. 1 and 2 , the cold solid surface comprises acylinder 12 that is capable of being maintained at low temperatures and can be rotated. However, any solid surface may be used, and it is not necessary that the surface be curved or that it move. A flat solid surface may also be used, or a curved surface that does not rotate may be used as well, so long as the surface is in a sold state and can be maintained at very low temperatures so as to substantially freeze the solution upon contact. Examples of solid surfaces include but are not limited to a rotating drum, a belt, a tray and the like. - The rate at which the solution is applied to the cold surface should be sufficient such that the solution is substantially frozen soon after contact with the cold surface. Preferably, the solution is substantially frozen in less than one minute upon contact with the cold surface. More preferably, the solution is applied to the cold surface such that the solution substantially freezes in less than one second upon contact with the cold surface. The solution should be applied to the surface such that the thickness of the resulting film layer of solution formed on the cold surface is sufficient to freeze within seconds upon contact. Preferably, the rate of application results in a film thickness of less than 5 millimeters, more preferably, less than about 1 mm, even more preferably less than about 0.2 mm, and yet even more preferably less than about 0.05 mm. If the film of solution is not substantially frozen within seconds of contact with the cold surface, the solution is being applied too quickly.
- The material of construction for the cold surface can be any material that is capable of being cooled to the desired temperature. Preferably, the material of construction is one that enables good heat transfer. Examples of particularly suitable materials of construction for the cold surface include metals, metal alloys, glass, and ceramics.
- The temperature at which the solution is held prior to being applied to the cold surface is not critical.
- The present invention includes cooling means located proximate to the second side of the cold solid surface, the cooling means adapted to cool the surface. The cooled solid surface can be cooled using any suitable means, including those utilizing a cryogenic solid, a cryogenic gas, a cryogenic liquid, or a heat transfer fluid capable of reaching cryogenic temperatures. A cryogenic solid is defined as a material that sublimes below the freezing point of water, such as, for example, carbon dioxide. A cryogenic gas means a material that is a gas below the freezing point of water, such as, for example, nitrogen. A cryogenic liquid is a material that is liquid below the freezing point of water, such as, for example, liquid nitrogen. In the embodiments shown in
FIGS. 1 and 2 , ahole 13 incylinder 12 permits insertion of dry ice into the inside ofcylinder 12 so as to cool the surface ofcylinder 12. In the embodiment shown inFIG. 3 , a cryogenicheat transfer agent 33 such as nitrogen or liquid carbon dioxide may be placed in contact with the cold surface, either directly or indirectly, so as to cool the surface. Other means for cooling the surface known to those skilled in the art may be used as well. - The temperature at which the cold surface should be cooled to will depend upon the organic solvent or solvents used in the solution. The cold solid surface should be cooled to a temperature that is below the freezing point of the freezable organic solvent prior to contacting the solution with the cold solid surface so as to ensure that the solution substantially freezes upon contact with the solid surface. The difference between the freezing point of the freezable organic solvent and the temperature of the cold surface will impact the rate of freezing of the solution.
- As used herein, the term “frozen solution” is defined to mean poorly water soluble drug particles and, optionally, one or more excipients, suspended in a frozen organic solvent matrix. Such frozen solution is formed once the solution is substantially frozen within seconds after contact with the cold surface.
- Preferably, the cold surface is cooled to a temperature of at least 5° C. below the freezing point of the organic solvent, more preferably at least 30° C. below the freezing point of the organic solvent, even more preferably at least 50° C. below the freezing point of the organic solvent, and most preferably at least 75° C. below the freezing point of the organic solvent. Desirably, the cold surface is maintained at a low temperature for entire period of time during which the process of the present invention is being carried out.
- The present invention also includes means for removing the frozen solution from the cold surface. As shown in
FIGS. 1 and 2 , one example of means for transferring the frozen solution includes aknife blade assembly 14 which flakes the frozen solution off of the cold surface and then allows the frozen solution to be gravity fed to a collecting surface or directly to further processing. Vibration, pressure, a brush or a blower or other methods utilizing a pressure differential are other appropriate means for removing the frozen solution from the cold surface. Alternatively, a non-stick coating on the cold surface would permit automatic removal of the frozen solution. -
FIGS. 1 and 2 also show aproduct tray 16 used as a collecting surface for the frozen solution once removed from thecylinder 12, and asecondary tray 17 as optional means for coolingproduct tray 16. By cooling the product tray, the solution is kept frozen until ready for further processing. - Means for transferring the frozen solution to subsequent processing step might be necessary for the present invention as well. In embodiments such those as shown in
FIGS. 1-2 , the frozen solution is gravity fed to the subsequent processing steps. In other embodiments, a conveyor could be used to transfer the frozen solution. - Solvent removal means are used to remove the organic solvent from the frozen solution, thereby generating the resulting drug particles. Suitable solvent removal means include sublimation and evaporation. Examples of sublimation techniques include but are not limited to lyophilization and atmospheric freeze drying, as known by those skilled in the art of solvent removal. Examples of evaporation techniques include but are not limited to distillation techniques and spray drying techniques, as known by those skilled in the art of solvent removal. In order to employ such evaporation techniques, the frozen solution is desirably first dispersed in a liquid that is miscible with the organic solvent but that does not solubilize the drug substance, such as, for example, water.
- The mean volume average particle size of the resulting drug particles after the particles are dispersed in water is from 0.05 microns to 150 microns, as measured using light scattering techniques. More preferably, the mean volume average particle size is 50 microns or less, even more preferably 25 microns or less, yet even more preferably 5 microns or less, and most preferably 1 micron or less.
- The resulting drug particles have a high surface area relative to particles that are not processed using the present invention. Advantageously, a high surface area can contribute to a relatively fast dissolution time. Preferably, the particles prepared according to the present invention have a surface area at least 2 m2/g, more preferably at least 5 m2/g, and even more preferably at least 10 m2/g, as measured using BET techniques known to those skilled in the art.
- The drug particles may be combined with any pharmaceutically-acceptable carrier in order to form a pharmaceutical formulation capable of, preferably, oral administration. The compositions of the inventions may also include optional excipients such as standard fillers, binders, or disintegrants readily known by those skilled in the art.
- The resulting drug particles exhibit enhanced in vitro dissolution rates as compared to the drug before being processed using the present invention. Preferably, the drug particles processed using the present invention exhibit an in vitro dissolution rate of at least 1.5 times better than that of the unprocessed drug, more preferably at least 5 times better than that of the unprocessed drug, and even more preferably at least 10 times better than that of the unprocessed drug, as measured using standard in vitro dissolution methods known to those skilled in the art. For example, within 2 minutes, if the unprocessed drug is 20% dissolved, then particles processed using the present invention would be at least 30% dissolved.
- Surprisingly, the resulting drug particles are substantially crystalline in nature, despite the fact that the present invention involves rapid freezing.
- The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the present invention. All parts and percentages are by weight, unless otherwise specified.
- Cyclosporin A is a drug substance that was purchased from POLI Industria Chimica S.P.A.
- Danazol is a drug substance that was purchased from Spectrum Chemical Co., & Diosynth Co.
- Ketoconazole, ketoprofen, naproxen, nifedipine, prednisone, triamcinalone acetonide, carbamazepine, and hydrocortisone acetate are drug substances that were purchased from the Spectrum Chemical Co.
- Pluronic F-127, is a stabilizer that was purchased from the Sigma Chemical Co.
- Pluronic F-108, Pluronic F-88 are stabilizers that were purchased from the BASF Co.
- Pluronic F-68, polyvinylpyrrolidone (PVP, 10K, 29K, 55K), SPAN 40, SPAN 60, and polyethylene glycol (PEG, 10K), are stabilizers that were purchased from the Aldrich Chemical Co.
- p-Xylene, t-amyl alcohol, 1,3,5-trioxane, sec-butyl acetate and cyclopentanol are solvents that were purchased from the Aldrich Chemical Co.
- t-Butanol, acetonitrile, acetone, tetrahydrofuran and ethyl acetate are solvents that were purchased from Fisher Scientific Co.
- Analytical Methods
- Particle Size Analysis.
- Analysis was performed on the bulk drug powder as received and on the powders prepared in Examples 1-60, after being redispersed in water, using a Beckman Coulter Counter.
- USP Dissolution Apparatus Method 2.
- Dissolution obtained using the following method is also referred to herein as “in vitro dissolution”. The dissolution media used varied with the drug substance, and is specified below. The dissolution media was heated to 37° C. and degassed. Dissolution was performed utilizing three vessels per experiment. 11 to 12 mg of drug particles prepared according to the present invention was added to each vessel for dissolution analysis. Dissolution samples were filtered automatically into test tubes containing 0.1 mL of acetonitrile, mixed with a vortex mixer, filtered and analyzed by HPLC. Samples were taken at 2, 5, 10, 15, 20, 30, 60, and 120 minutes. At the 60 min. point the agitation speed was increased to 200 rpm to ensures complete dissolution by 120 minutes. The 120 min. reading is the infinity time reading and the infinity time is used to calculate the potency. Dissolution times were measured for the bulk drug substance as received as well as the drug particles prepared according to the present invention for each of Examples 1-60. Dissolution Media for the various drug substances used in Examples 1-60 were as follows:
- For Naproxen, Carbamazapine & Ketoprofen:
- The dissolution media was deionized water containing 5.0 wt. % sodium chloride.
- For Danazol:
- The dissolution media was deionized water containing 0.75 wt. % SLS, and 1.21 wt. % Tris(hydroxymethyl)aminomethane, and was adjusted to pH 9.
- For Cyclosporin A:
- The dissolution media was deionized water containing 0.1 wt. % SLS.
- For Ketoconazole:
- The dissolution media was deionized water containing 0.5 wt. % SLS.
- For Nifedipine:
- The dissolution media was deionized water containing 0.3 wt. % SLS and 3.0 wt. % sodium chloride.
- For Prednisone & Triamcinalone Acetonide:
- The dissolution media was deionized water containing 10.0 wt. % sodium chloride.
- For Hydrocortisone Acetate:
- The dissolution media was deionized water containing 0.3 wt. % sodium sodium dodecylsulfate (SDS).
- Percent Crystallinity.
- Crystallinity was determined by X-ray diffraction methods using a Bruker D-8 automated diffractometer.
- Atmospheric Freeze Drying (ATMFD).
- ATMFD was one method of solvent removal used in the following examples. Heat transfer fluid was circulated through the circulating jacket of the heat exchanger, that was used to cool the drying gas then to the jacket of the ATMFD unit. Chilled nitrogen gas is flowed through the bottom of the ATMFD unit to sublime the solvent(s) away from the drug (s) and fluidizing the solids. The ATMFD unit and the nitrogen gas temperature are slowly warmed to ambient temperature. After the ATMFD portion of the process was complete the solid was collected from either the cyclone or the ATMFD Unit.
- Freeze Drying.
- Freeze drying was an alternative solvent removal method used in some of the following examples. The frozen solution that was prepared was transferred to ajar cooled with dry ice. The processed solid in the chilled container was placed on a Virtis freeze dryer and dried for app. 12-24 hr at approximately 100 mtorr vacuum.
- For each of Examples 1-60, solutions were made using the materials listed in Table A.
-
TABLE A Wt % Wt % Wt % Example Drug drug Solvent(s) solvent Stabilizer(s) stabilizer 1 Danazol (bottle) 1.44 t-Butanol 95.68 Pluronic F-127, & 2.88 PVP(10k) (50/50) wt. % ratio 2 Ketoconazole 1.22 t-Butanol 97.56 Pluronic F-127 1.22 (sprayed) 3 Danazol 2.13 t-Butanol 95.74 Pluronic F-127 2.13 (sprayed) 4 Carbamazepine 1.92 t-Butanol 96.16 Pluronic F-127 1.92 5 Carbamazepine 0.50 p-Xylene 99.00 Pluronic F-127 0.50 6 Carbamazepine 1.92 t-Butanol 96.16 Pluronic F-127 1.92 7 Carbamazepine 0.95 t-Butanol 98.10 Pluronic F-88 0.95 8 Carbamazepine 0.95 t-Butanol 98.08 PVP(10k) 0.97 9 Carbamazepine 1.00 t-Butanol 98.00 Pluronic F-127, & 1.00 PVP(10k) (50/50) wt. % ratio 10 Cyclosporin A 1.92 t-Butanol 96.16 Pluronic F-127 1.92 11 Cyclosporin A 1.92 t-Butanol 96.16 Pluronic F-127 1.92 12 Danazol 2.83 t-Butanol 94.34 Pluronic F-127 2.83 13 Danazol 3.70 t-Butanol 92.60 Pluronic F-127 3.70 14 Danazol 4.55 t-Butanol 90.90 Pluronic F-127 4.55 15 Danazol 1.61 t-Butanol 96.78 Pluronic F-127 1.61 16 Danazol 1.47 t-Butanol 98.04 Pluronic F-108, & 0.49 PVP(55k) (50/50) wt. % ratio 17 Danazol 0.93 t-Butanol 98.08 PVP(10k) 0.99 18 Danazol 0.90 t-Butanol 98.14 PVP(29k) 0.96 19 Danazol 0.98 t-Butanol 98.04 PVP(55k) 0.98 20 Danazol 1.04 t-Butanol 97.93 PEG(10k) 1.03 21 Hydrocortisone 1.00 t-Butanol 98.00 Pluronic F-127 1.00 Acetate 22 Hydrocortisone 0.97 t-Butanol 98.03 Pluronic F-127, & 1.00 Acetate PEG(10k) (50/50) wt. % ratio 23 Hydrocortisone 0.92 t-Butanol 98.17 Pluronic F-68 0.91 Acetate 24 Hydrocortisone 0.95 t-Butanol 98.11 PEG(10k) 0.94 Acetate 25 Ketoconazole 1.17 t-Butanol 97.66 Pluronic F-127 1.17 26 Ketoconazole 0.98 t-Butanol 98.04 Pluronic F-127 0.98 27 Ketoprofen 1.92 t-Butanol 96.16 Pluronic F-127 1.92 28 Ketoprofen 1.92 t-Butanol 96.16 Pluronic F-127 1.92 29 Ketoprofen 1.00 t-Butanol 97.93 Pluronic F-88 1.07 30 Naproxen 1.61 t-Butanol 96.78 Pluronic F-127 1.61 31 Naproxen 1.61 t-Butanol 96.78 Pluronic F-127 1.61 32 Naproxen 1.00 t-Butanol, & 98.00 Pluronic F-127 1.00 t-Amyl Alcohol (60/40) wt. % ratio 33 Naproxen 1.60 t-Butanol 98.00 Pluronic F-127, & 0.40 PVP(29k) (50/50) wt. % ratio 34 Naproxen 1.40 p-Xylene, & 98.00 Pluronic F-127 0.60 1,3,5-Trioxane (80/20) wt. % ratio 35 Naproxen 9.94 t-Butanol 80.10 Pluronic F-127 9.96 36 Naproxen 1.00 t-Butanol, & 97.99 Pluronic F-127 1.01 Cyclopentanol (80/20) wt. % ratio 37 Naproxen 1.67 t-Butanol, 96.67 Pluronic F-127 1.66 (deionized water also added to assist in solubilizing the stabilizer). (50/50) wt. % ratio 38 Naproxen 1.00 t-Butanol, & 98.00 Pluronic F-127 1.00 Acetonitrile (90/10) wt. % ratio 39 Naproxen 13.73 t-Butanol, & 80.38 Pluronic F-127 5.89 Acetone (90/10) wt. % ratio 40 Naproxen 1.00 t-Butanol, & 98.00 Pluronic F-127 1.00 Ethyl Acetate (90/10) wt. % ratio 41 Naproxen 1.00 t-Butanol, & 98.00 Pluronic F-127 1.00 sec-Butyl Acetate (90/10) wt. % ratio 42 Naproxen 1.00 t-Butanol, & 98.00 Pluronic F-127 1.00 1,3,5-Trioxane (50/50) wt. % ratio 43 Naproxen 4.11 p-Xylene 94.13 Pluronic F-127 1.76 44 Naproxen 0.95 t-Butanol 98.11 SPAN 40 0.94 45 Naproxen 0.94 t-Butanol 98.10 Pluronic F-127 & 0.96 SPAN 40 (50/50) wt. % ratio 46 Naproxen 1.00 t-Butanol 98.01 SPAN 60 0.99 47 Naproxen 0.98 t-Butanol 98.01 Pluronic F-127 & 1.01 SPAN 60 (50/50) wt. % ratio 48 Nifedipine 1.92 t-Butanol 96.16 Pluronic F-127 1.92 49 Nifedipine 1.92 t-Butanol 96.16 Pluronic F-127 1.92 50 Nifedipine 0.95 t-Butanol 98.06 Pluronic F-127, & 0.99 PVP(55k) (50/50) wt. % ratio 51 Prednisone 0.89 t-Butanol 98.22 Pluronic F-127 0.89 52 Prednisone 0.89 t-Butanol 98.22 Pluronic F-127 0.89 53 Prednisone 0.94 t-Butanol 98.07 Pluronic F-108 0.99 54 Triamcinalone 1.92 t-Butanol 96.16 Pluronic F-127 1.92 Acetonide 55 Triamcinalone 1.92 t-Butanol 96.16 Pluronic F-127 1.92 Acetonide 56 Triamcinalone 0.76 t-Butanol 98.47 PVP(10k) 0.77 Acetonide 57 Naproxen 2.50 t-Butanol 94.99 Pluronic F-127 2.51 58 Naproxen 5.83 t-Butanol 91.67 Pluronic F-127 2.50 59 Naproxen 5.93 Acetonitrile 91.41 Pluronic F-127 2.66 60 Naproxen 3.67 Tertahydrofuran, 94.73 Pluronic F-127 1.60 (deionized water also added to assist in solubilizing the stabilizer). (68/32) wt. % ratio - A 125-mL freeze-drying bottle was cooled to −78° C. in a dry-ice acetone bath. The prepared solution was slowly pipetted into the cooled freeze-drying bottle. The frozen solid in the freeze drying bottle was then placed on a freeze drying unit and allowed to lyophylize until completely dry, resulting in 0.9 g of flowable white powder. Particle size analysis results and dissolution times determined both before and after processing are shown in Table B.
- The apparatus shown in
FIG. 1 was used.Cylinder 12 was cooled to −78° C. with dry ice. The solution was sprayed ontocylinder 12 for approximately 10 minutes. The resulting frozen solid was removed by use ofknife blade assembly 14, and was collected in cooledproduct collection tray 16. The collected material was transferred by hand to a solvent removal unit. Particle size analysis results and dissolution times determined both before and after carrying out the process of the present invention are shown in Table B. - The apparatus shown in
FIG. 2 was used.Cylinder 12 was cooled to −78° C. with dry ice. The solution was dripped ontocylinder 12 for approximately 10 minutes using an addition funnel. The resulting frozen solid was removed by use ofknife blade assembly 14 and collected in a cooledproduct collection tray 16. The collected product was then transferred by hand to the solvent removal step. Particle size analysis results and dissolution times determined both before and after carrying out the process of the present invention are shown in Table B. - The apparatus shown in
FIG. 2 was used.Cylinder 12 was cooled to −78° C. with dry ice. The solution was dripped ontocylinder 12 for approximately 10 minutes using an addition funnel. The resulting frozen solid was removed by use ofknife blade assembly 14 and collected in a cooledproduct collection tray 16. The collected product was dispersed in deionized water. The dispersed solid/aqueous/solvent slurry was then taken directly into the solvent removal step. Particle size analysis results and dissolution times determined both before and after carrying out the process of the present invention are shown in Table B. -
TABLE B Dissolution Dissolution of PSA* of of bulk processed PSA* of processed drug after drug after Drying bulk drug drug 2 minutes 2 minutes % Example Drug Method (microns) (microns) (wt %) (wt %) crystallinity 1 Danazol (bottle) Freeze dried 24.86 0.301 56.42 97.1 — 2 Ketoconazole ATMFD 13.5 7.334 26.1 100.77 — (sprayed) 3 Danazol (sprayed) ATMFD 24.86 23.47 56.42 103.03 — 4 Carbamazepine ATMFD 391.4 30.07 4.83 74.62 79.2 5 Carbamazepine ATMFD 391.4 22.58 4.83 77.30 — 6 Carbamazepine Freeze dried 391.4 54.13 4.83 48.23 — 7 Carbamazepine Freeze dried 391.4 103.10 4.83 77.52 — 8 Carbamazepine Freeze dried 391.4 92.43 4.83 65.37 — 9 Carbamazepine Freeze dried 391.4 74.26 4.83 77.50 — 10 Cyclosporin A ATMFD 53.89 38.02 3.39 86.4 amorphous 11 Cyclosporin A Freeze dried 53.89 22.04 3.39 26.02 — 12 Danazol ATMFD 24.86 17.60 56.42 100.17 70.4 13 Danazol ATMFD 24.86 43.29 56.42 99.22 — 14 Danazol ATMFD 24.86 34.54 56.42 104.15 — 15 Danazol Freeze dried 24.86 15.47 56.42 99.75 — 16 Danazol Freeze dried 24.86 7.011 56.42 97.55 — 17 Danazol Freeze dried 24.86 4.377 56.42 101.41 — 18 Danazol Freeze dried 24.86 108.50 56.42 103.01 — 19 Danazol Freeze dried 24.86 20.80 56.42 89.52 — 20 Danazol Freeze dried 24.86 16.53 56.42 93.31 — 21 Hydrocortisone ATMFD 17.07 7.447 21.16 97.46 91.2 Acetate 22 Hydrocortisone Freeze dried 17.07 3.949 21.16 100.49 — Acetate 23 Hydrocortisone Freeze dried 17.07 9.740 21.16 94.65 — Acetate 24 Hydrocortisone Freeze dried 17.07 27.94 21.16 91.10 — Acetate 25 Ketoconazole ATMFD 13.50 11.64 26.10 98.85 94.6 26 Ketoconazole Freeze dried 13.50 76.66 26.10 78.8 — 27 Ketoprofen ATMFD 42.73 27.60 2.81 92.39 74.7 28 Ketoprofen Freeze dried 42.73 82.93 2.81 57.06 — 29 Ketoprofen Freeze dried 42.73 91.82 2.81 72.70 — 30 Naproxen ATMFD 24.07 13.28 0.29 64.05 — 31 Naproxen Freeze dried 24.07 2.193 0.29 71.57 90.5 32 Naproxen Freeze dried 24.07 0.847 0.29 99.96 — 33 Naproxen Freeze dried 24.07 0.859 0.29 70.23 — 34 Naproxen Freeze dried 24.07 9.858 0.29 76.77 — 35 Naproxen Freeze dried 24.07 1.272 0.29 65.77 — 36 Naproxen Freeze dried 24.07 56.33 0.29 94.77 — 37 Naproxen Freeze dried 24.07 84.76 0.29 70.69 — 38 Naproxen Freeze dried 24.07 10.76 0.29 70.54 — 39 Naproxen Freeze dried 24.07 18.24 0.29 76.43 — 40 Naproxen Freeze dried 24.07 44.04 0.29 88.77 — 41 Naproxen Freeze dried 24.07 33.80 0.29 87.16 — 42 Naproxen Freeze dried 24.07 0.807 0.29 74.17 — 43 Naproxen Freeze dried 24.07 1.114 0.29 78.46 — 44 Naproxen Freeze dried 24.07 118.40 0.29 37.34 — 45 Naproxen Freeze dried 24.07 79.69 0.29 44.31 — 46 Naproxen Freeze dried 24.07 74.51 0.29 34.71 — 47 Naproxen Freeze dried 24.07 67.90 0.29 40.82 — 48 Nifedipine ATMFD 244.9 39.53 4.70 83.34 77.9 49 Nifedipine Freeze dried 244.9 16.45 4.70 56.65 — 50 Nifedipine Freeze dried 244.9 19.13 4.70 76.75 — 51 Prednisone ATMFD 3.263 15.30 0.97 81.42 81.7 52 Prednisone Freeze dried 3.263 11.52 0.97 89.19 — 53 Prednisone Freeze dried 3.263 14.31 0.97 80.24 — 54 Triamcinalone ATMFD 7.707 11.60 5.38 47.56 38.2 Acetonide 55 Triamcinalone Freeze dried 7.707 9.176 5.38 51.90 — Acetonide 56 Triamcinalone Freeze dried 7.707 15.08 5.38 32.31 — Acetonide 57 Naproxen Freeze dried 24.07 3.622 0.29 63.20 — 58 Naproxen Freeze dried 24.07 3.282 0.29 59.84 — 59 Naproxen Freeze dried 24.07 6.477 0.29 70.23 — 60 Naproxen Freeze dried 24.07 10.59 0.29 82.22 — *PSA means “particle size analysis”.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/861,046 US20160074328A1 (en) | 2003-01-15 | 2015-09-22 | Drug Particles From Freezing Onto A Surface |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44053503P | 2003-01-15 | 2003-01-15 | |
US10/639,361 US9175906B2 (en) | 2003-01-15 | 2003-08-12 | Drug particles from freezing onto a surface |
US14/861,046 US20160074328A1 (en) | 2003-01-15 | 2015-09-22 | Drug Particles From Freezing Onto A Surface |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/639,361 Division US9175906B2 (en) | 2003-01-15 | 2003-08-12 | Drug particles from freezing onto a surface |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160074328A1 true US20160074328A1 (en) | 2016-03-17 |
Family
ID=32771826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/639,361 Active 2025-04-12 US9175906B2 (en) | 2003-01-15 | 2003-08-12 | Drug particles from freezing onto a surface |
US14/861,046 Pending US20160074328A1 (en) | 2003-01-15 | 2015-09-22 | Drug Particles From Freezing Onto A Surface |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/639,361 Active 2025-04-12 US9175906B2 (en) | 2003-01-15 | 2003-08-12 | Drug particles from freezing onto a surface |
Country Status (8)
Country | Link |
---|---|
US (2) | US9175906B2 (en) |
EP (1) | EP1589948A1 (en) |
JP (1) | JP4933732B2 (en) |
KR (1) | KR20050096936A (en) |
CN (1) | CN1731984A (en) |
AU (1) | AU2003296893A1 (en) |
CA (1) | CA2513006A1 (en) |
WO (1) | WO2004064808A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10849867B2 (en) | 2015-09-01 | 2020-12-01 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory response |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021188564A1 (en) | 2020-03-16 | 2021-09-23 | First Wave Bio, Inc. | Methods of treating covid-19 with a niclosamide compound |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026502A1 (en) | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
EP1798504A1 (en) * | 2005-12-19 | 2007-06-20 | Koninklijke Philips Electronics N.V. | Method of making dried particles |
CN101511170B (en) * | 2005-12-22 | 2014-03-26 | 奥克伍德药业有限公司 | Sublimable sustained release delivery system and method of making same |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
WO2008124928A1 (en) * | 2007-04-13 | 2008-10-23 | Christopher Culligan | Freezable unit dosage delivery system and method of preparation |
ES2717154T3 (en) | 2007-06-22 | 2019-06-19 | Univ Texas | Formation of stable submicrometer peptide or protein particles by thin film freezing |
CA2723314C (en) | 2008-02-13 | 2017-01-10 | The Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
CN101618019B (en) * | 2008-07-01 | 2011-08-03 | 上海通用药业股份有限公司 | Triamcinolone acetonide acetate particle, and preparation method and medicinal composition thereof |
TWI580441B (en) * | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | Stabilized pharmaceutical sub-micron suspensions and methods of forming same |
WO2010102802A1 (en) * | 2009-03-11 | 2010-09-16 | Borregaard Industries Limited, Norge | Method for drying microfibrilated cellulose |
CA2791693C (en) | 2010-03-12 | 2018-11-27 | Niven Rajin Narain | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
EP2601973A1 (en) | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
CN110607552B (en) * | 2018-10-30 | 2024-02-20 | 中国科学院化学研究所 | Method for preparing monocrystal or amorphous substance by using aqueous solution |
WO2020088481A1 (en) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | Method for preparing drug or drug intermediate single crystal or amorphous substance |
CN111735281B (en) * | 2020-06-05 | 2022-04-08 | 浙江科恩实验设备有限公司 | Quick-drying type water dripping frame |
CN112539606A (en) * | 2020-12-01 | 2021-03-23 | 镇江波菲尔生物科技有限公司 | Laboratory freeze dryer with antistatic function for biological medicine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US20050238724A1 (en) * | 2002-04-23 | 2005-10-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing lamotrigine particles of defined morphology |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3309777A (en) * | 1963-08-30 | 1967-03-21 | Robert S Hutton | Process for making uniformly constituted finely divided particulate material |
US3313032A (en) * | 1966-07-28 | 1967-04-11 | George J Malecki | Freeze-drying process and apparatus |
US3932943A (en) * | 1970-08-14 | 1976-01-20 | E. I. Du Pont De Nemours And Company | Method of preparation of lyophilized biological products |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
CA2051092C (en) * | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
DE69502179D1 (en) * | 1994-02-09 | 1998-05-28 | Kinerton Ltd | METHOD FOR DRYING A MATERIAL FROM A SOLUTION |
WO2002060411A2 (en) * | 2001-01-30 | 2002-08-08 | Board Of Regents University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
-
2003
- 2003-08-12 KR KR1020057013059A patent/KR20050096936A/en not_active Application Discontinuation
- 2003-08-12 AU AU2003296893A patent/AU2003296893A1/en not_active Abandoned
- 2003-08-12 CN CNA038258234A patent/CN1731984A/en active Pending
- 2003-08-12 JP JP2004566896A patent/JP4933732B2/en not_active Expired - Lifetime
- 2003-08-12 US US10/639,361 patent/US9175906B2/en active Active
- 2003-08-12 WO PCT/US2003/025338 patent/WO2004064808A1/en active Application Filing
- 2003-08-12 EP EP03815476A patent/EP1589948A1/en not_active Withdrawn
- 2003-08-12 CA CA002513006A patent/CA2513006A1/en not_active Abandoned
-
2015
- 2015-09-22 US US14/861,046 patent/US20160074328A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US20050238724A1 (en) * | 2002-04-23 | 2005-10-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing lamotrigine particles of defined morphology |
Non-Patent Citations (4)
Title |
---|
Charoenchaitrakool et al., Micronization by Rapid Expansion of Supercritical Solutions to Enhance the Dissolution Rates of Poorly Water-Soluble Pharmaceuticals, 12/04/2000, Ind. Eng. Chem. Res., vol. 39, pp.4794-4802. (Year: 2000) * |
Drugbank Online, Ibuprofen sodium, last accessed 03/02/2023, https://go.drugbank.com/salts/DBSALT001483 (Year: 2023) * |
Rasenack et al., Dissolution Rate Enhancement by in Situ Micronization of Poorly Water-Soluble Drugs, 12/2002, Pharmaceutical Research, Vol. 19 No. 12, pp. 1894-1900. * |
Suzuki et al., Studeson Methods of Particle Size Reduction of Medicinal Compounds., 1979, Chem. Pharm. Bull., vol. 27 no. 5, pp. 1214-1222. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10849867B2 (en) | 2015-09-01 | 2020-12-01 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory response |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021188564A1 (en) | 2020-03-16 | 2021-09-23 | First Wave Bio, Inc. | Methods of treating covid-19 with a niclosamide compound |
Also Published As
Publication number | Publication date |
---|---|
WO2004064808A1 (en) | 2004-08-05 |
US9175906B2 (en) | 2015-11-03 |
JP2006514076A (en) | 2006-04-27 |
CA2513006A1 (en) | 2004-08-05 |
JP4933732B2 (en) | 2012-05-16 |
KR20050096936A (en) | 2005-10-06 |
AU2003296893A1 (en) | 2004-08-13 |
CN1731984A (en) | 2006-02-08 |
EP1589948A1 (en) | 2005-11-02 |
US20040137070A1 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160074328A1 (en) | Drug Particles From Freezing Onto A Surface | |
CA2458889C (en) | A process for preparing crystalline drug particles by means of precipitation | |
EP1335705B1 (en) | Preparation of drug particles using evaporation precipitation into aqueous solutions | |
US8263128B2 (en) | Solid pharmaceutical dispersions with enhanced bioavailability | |
Savjani et al. | Drug solubility: importance and enhancement techniques | |
US8551526B2 (en) | Preparation of drug particles using evaporation precipitation into aqueous solutions | |
US5302401A (en) | Method to reduce particle size growth during lyophilization | |
JP2005531521A (en) | Drag fine particles | |
KR20120089815A (en) | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin | |
EP1741424B1 (en) | Solid pharmaceutical dispersions with enhanced bioavailabilty | |
Barman et al. | Development of highly stable nifedipine solid–lipid nanoparticles | |
Surasarang et al. | Pharmaceutical cryogenic technologies | |
US20040028747A1 (en) | Crystalline drug particles prepared using a controlled precipitation process | |
CN101090720A (en) | Nanoparticulate compositions of tubulin inhibitor compounds | |
Sahakijpijarn et al. | Pharmaceutical Cryogenic Technologies 11 | |
MXPA98006463A (en) | Solid pharmaceutical dispersions with better biodisponibility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |